CCNE1 and serous adenocarcinoma: Multi‐institutional validation of the prognostic value of cyclin E1 high‐level amplification and overexpression in 3029 tubo‐ovarian high‐grade serous carcinoma cases support its value as a prognostic biomarker in this disease.